Fulvio Lonardo, MD


Professor
Department of Pathology
Harper University Hospital
3990 John R
Detroit, MI 48201, USA

Biography

EDUCATION
• (1978-1985) MD (summa cum laude), 2nd Medical School, Naples, Italy

POSTGRADUATE TRAINING
• (1986-1987) Guest Researcher, Laboratory of Cellular and Molecular Biology NCI, Bethesda
• (1987-1990) Fogarty International fellow, Laboratory of Cellular and Molecular Biology NCI, Bethesda
• (1990-1993) Residency in Anatomic Pathology, University of Rochester Medical Center, Rochester, NY
• (1993-1994) Wilmot Cancer Research fellow, University of Rochester Medical Center, Rochester, NY
• (1994-1995) Oncologic Anatomic Pathology Fellow, Memorial Sloan Kettering Cancer Center, NYC
• (1995-1999) Experimental Pathology Fellow, Memorial Sloan Kettering Cancer Center, New York, NY

FACULTY APPOINTMENTS
• (1999-2005) Assistant Professor, Harper Hospital Wayne State University School of Medicine, Detroit, MI
• (2006-2011) Associate Professor, Harper Hospital Wayne State University School of Medicine, Detroit, MI
• (2011-Present) Professor, Harper Hospital Wayne State University School of Medicine, Detroit, MI

Research Interest

His research interests include: Molecular pathogenesis of lung cancer, Relations between molecular and morphological features of lung cancer, Epidemiological aspects of lung cancer.

Scientific Activities

HONORS AND AWARDS
• (1987) Fogarty International Fellowship, National Institutes of Health
• (1993) Wilmot Cancer Research Fellowship, URMC
• (2010) Residents teacher award

MEMBERSHIPS
• (1999- Present) International Academy of Pathology
• (2002-Present) American Association for Cancer Research

Publications

Peer-reviewed publications (in chronological order)
1. Segatto O, Lonardo F, Pierce JH, Bottaro DP, Di Fiore PP. The role of autophosphorylation in modulation of erbB-2 transforming function. New Biol. 1990; 2(2): 187-195.
2. Di Fiore PP, Segatto O, Lonardo F, Fazioli F, Pierce JH, Aaronson SA. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol. 1990; 10(6): 2749-2756. doi: 10.1128/MCB.10.6.2749
3. Di Fiore PP, Segatto O, Lonardo F, Fazioli F, Pierce JH, Aaronson SA. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 1990; 2(11): 992-1003.
4. Segatto O, Lonardo F, Wexler D, et al. The juxta membrane regions of the epidermal growth factor receptor and gp185erbB-2 determine the specificity of signal transduction. Mol Cell Biol. 1991; 11(6): 3191-3202. doi: 10.1128/MCB.11.6.3191
5. Pierce JH, Arnstein P, DiMarco E, et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene. 1991; 6(7): 1189-1194.
6. Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995; 147(6): 1592-1599.
7. Langenfeld J, Lonardo F, Kiyokawa H, et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene. 1996; 13(9): 1983-1990.
8. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer. 1997; 79(8): 1541-1547.
9. Albanell J, Lonardo F, Rusch V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst. 1997; 89(21): 1609-1615. doi: 10.1093/jnci/89.21.1609
10. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst. 1999; 91(4): 373-379. doi: 10.1093/jnci/91.4.373
11. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer. 1999; 80(2): 199-204.
12. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 1999; 59(10): 2470-2476.
13. Califano J, Westra WH, Koch W, et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst. 1999; 91(7): 599-604. doi: 10.1093/jnci/91.7.599
14. Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol. 2000; 9(1): 1-8.
15. Boyle JO, Lonardo F, Chang JH, Klimstra D, Rusch V, Dmitrovsky E. Multiple high-grade bronchial dysplasia and squamous cell carcinoma: concordant and discordant mutations. Clin Cancer Res. 2001; 7(2): 259-266.
16. Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and Power Blot. Clin Cancer Res. 2002; 8(12): 3910-3921.
17. Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res. 2002; 8(1): 54-60.
18. Yoo GH, Piechocki MP, Lonardo F, et al. In vivo characteristics of HPV-immortalized and carcinogen transformed oral keratinocytes. Laryngoscope. 2002; 112(9): 1672-1679. doi: 10.1097/00005537-200209000-00027
19. Lechner JF, Wang Y, Siddiq F, et al. Human lung cancer cells and tissues partially recapitulate the homeobox gene expression profile of embryonic lung. Lung Cancer. 2002; 37(1): 41-47. doi: 10.1016/S0169-5002(02)00036-3
20. Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003; 42(3): 270-279. doi: 10.1046/j.1365-2559.2003.01583.x
21. Lonardo F, Pass HI, Lucas DR. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol. 2003; 11(1): 51-55.
22. Shehadeh NJ, Vernick J, Lonardo F, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: a case report and review of the literature. Am J Otolaryngol. 2004; 25(1): 48-53. doi: 10.1016/S0196-0709(03)00096-6
23. Otero GJE, Youssef E, Enamorado II, et al. Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. Am J Otolaryngol. 2004; 25(4): 231-239. doi: 10.1016/j.amjoto.2004.01.001
24. Yoo GH, Piechocki MP, Oliver J, et al. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer. Laryngoscope. 2004; 114(11): 1871-189. doi: 10.1097/01.mlg.0000147914.51239.ed
25. Siddiq F, Sarkar FH, Wali A, Pass HI, Lonardo F. Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer. 2004; 45(2): 197-205. doi: 10.1016/j.lungcan.2004.01.020
26. Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004; 10(3): 849-859. doi: 10.1158/1078-0432.CCR-0607-3
27. Yoo GH, Lin HS, Iskander AJ, et al. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Laryngoscope. 2005; 115(11): 1938-1946. doi: 10.1097/01.mlg.0000177456.90870.94
28. Wali A, Morin PJ, Hough CD, et al. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer. 2005; 48(1): 19-29. doi: 10.1016/j.lungcan.2004.10.011
29. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15): 1564-1573. doi: 10.1056/NEJMoa051185
30. Schwartz AG, Prysak GM, Murphy V, et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res. 2005; 11(20): 7280-7287. doi: 10.1158/1078-0432.CCR-05-0498
31. Lonardo F, Li X, Siddiq F, et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer. 2006; 51(1): 31-39. doi: 10.1016/j.lungcan.2005.07.011
32. Piechocki MP, Yoo GH, Dibbley SK, Amjad EH, Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int J Cancer. 2006; 119(2): 441-454. doi: 10.1002/ijc.21837
33. Lin HS, Talwar HS, Tarca AL, Ionan A, et al. Autoantibody approach for serum-based detection of head and neck cancer. Cancer epidemiology, biomarkers & prevention. 2007; 16(11): 2396-2405. doi: 10.1158/1055-9965.EPI-07-0318
34. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clinical cancer research. 2007; 13(17): 4964-4973. doi: 10.1158/1078-0432.CCR-07-1041
35. Yoo GH, Tran VR, Lemonnier LA, et al. BMS-275183-induced gene expression patterns in head and neck carcinoma. American Journal of Otolaryngology. 2007; 28(5): 309-315. doi: 10.1016/j.amjoto.2006.10.001
36. Francis WP, Rodriques DM, Perez NE, Lonardo F, Weaver D, Webber JD. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS : Journal of the Society of Laparoendoscopic Surgeons / Society of Laparoendoscopic Surgeons. 2007; 11(1): 142-147.
37. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Research. 2007; 67(14): 6825-6843. doi: 10.1158/0008-5472.CAN-07-0765
38. Frey AB, Wali A. Pass H, Lonardo F. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology. 2007; 50(6): 720-726. doi: 10.1111/j.1365-2559.2007.02675.x
39. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk in non small cell lung cancer in women. Journal of Clinical Oncology. 2007; 25(36): 5785-5792. doi: 10.1200/JCO.2007.13.3975
40. Van Dyke AL, Cote ML, Prysak G, et al. Schwartz A:COX 2/EGFR. Expression and Survival among Women with Adenocarcinoma of the Lung. Carcinogenesis. 2008; 29 (9): 1781-1787 doi: 10.1093/carcin/bgn107
41. Piechocki MP, Dibbey SK, Lonardo F, Yoo G. Gefitinib prevents cancer progression in mice expressing the activated rat Her2/neu. Int J Cancer. 2008; 122: 1722-1729. doi: 10.1002/ijc.23231
42. Yoo GH, Subramanian G, Piechocki MP, et al. Effect of Docetaxel on the surgical tumor microenvironment of head and neck cancer in murine model. Arch Otolaryngol Head Neck Surg. 2008; 134(7): 735-742. doi: 10.1001/archotol.134.7.735
43. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F. Nuclear, compared to combined nuclear and cytoplasmic expression of maspin is linked in lung adenocarcinoma to reduced VEGFA levels and in stage I, improved survival. Histopathology. 2009; 54: 590-597. doi: 10.1111/j.1365-2559.2009.03260.x
44. Yoo GH, Subraimanian G, Ezzat WH, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of Otolaryngology-Head & Neck Surgery. 2009; 135(9): 869-874. doi: 10.1001/archoto.2009.122
45. Ivanova AV, Goparaju CM, Ivanov SV, et al. Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. Clinical Cancer Research. 2009; 15(8): 2602-2611. doi: 10.1158/1078-0432.CCR-08-2755
46. Yoo GH, Kafri Z, Ensley JF, et al. XRP 6258 Induced gene expression pattern in Head and Neck carcinoma. Laryngoscope. 2010; 120(6): 1114-1119. doi: 10.1002/lary.20559
47. Yoo GH, Tulunay OE, Trans VR, et al. Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model. Am J Otorlaryngol. 2010; 31(2): 78-83. doi: 10.1016/j.amjoto.2008.10.002
48. Cote ML, Haddad R, Edwards E, et al. Frequency and type of EGFR mutations in African Americans with NSCLC. J Thorac Oncol. 2011; 6: 627-630. doi: 10.1097/JTO.0b013e31820a0ec0
49. Li X, Kaplun A, Lonardo F, et al. HDAc1 inhibition by maspin abrogates epigenetic silencing of GST-Pi in prostate carcinoma cells. Mol Can Res. 2011; 9(6): 733-745.
50. Weiner IS, Lonardo F, Johnson SC, Deppe G. Merkel cell carcinoma in a patient with non invasive vulvar Paget’s disease. AM J Obtet Gynecol. 2012; 207(1): e9-e11. doi: 10.1016/j.ajog.2012.03.028
51. Hillman GG, Gupta VS, Lonardo F, et al. Soy Isoflavones Protect Normal Lung Tissue from Radiation-Induced Injury . Journal of Thoracic Oncology. 2013; 8(11): 1356-1364. doi: 10.1016/j.radonc.2011.10.020
52. Hillman GG, Gupta VS, Hoogstra DJ, et al. Joiner: Differential Effect of Soy Isoflavones in Enhancing High Dose Radiotherapy and Protecting Lung Tissue in a Pre Clinical Model of Lung Carcinoma. Radiotherapy and Oncology. 2013.
53. SH Dzinic, A Kaplun, X Li, et al. Identification of an Intrinsic Motif Critical for Maspin Subcellular Localization and Function. PLoS One. 2013; 8(11): e74502.doi: 10.1371/journal.pone.0074502
54. Hillman GG, Lonardo F, Hoogstra DJ, et al. Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. Translational Oncology. doi: 10.1016/j.tranon.2014.04.002
55. Lonardo F, Guan H, Dzinic S,Sheng S. Maspin Expression Patterns Differ in the Invasive vs. Lepidic Growth Pattern of Pulmonary Adenocarcinoma. Histopathology. 2014. doi: 10.1111/his.12485